{"pmid":32374026,"title":"Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.","text":["Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.","This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on Immune Thrombocytopenia (ITP) during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.","Br J Haematol","Pavord, S","Thachil, J","Hunt, B","Murphy, M","Lowe, G","Laffan, M","Makris, M","Newland, A","Provan, D","Grainger, J","Hill, Q","32374026"],"abstract":["This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on Immune Thrombocytopenia (ITP) during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum."],"journal":"Br J Haematol","authors":["Pavord, S","Thachil, J","Hunt, B","Murphy, M","Lowe, G","Laffan, M","Makris, M","Newland, A","Provan, D","Grainger, J","Hill, Q"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374026","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16775","locations":["thrombocytopenia","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138496463536128,"score":9.490897,"similar":[{"pmid":32420612,"title":"COVID-19-associated immune thrombocytopenia.","text":["COVID-19-associated immune thrombocytopenia.","Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection.","Br J Haematol","Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G","32420612"],"abstract":["Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection."],"journal":"Br J Haematol","authors":["Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420612","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16850","locations":["Thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667254896710123520,"score":380.92426},{"pmid":32420629,"title":"Evans syndrome in a patient with COVID-19.","text":["Evans syndrome in a patient with COVID-19.","Evans syndrome (ES) is a rare condition characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia (ITP). While the precise pathophysiology is not entirely understood, it is believed that dysregulation of the immune system is a primary contributor to the condition. ES has been observed in viral infections including hepatitis C, cytomegalovirus, varicella-zoster, and Epstein-Barr viruses (1-4). Initial cases of coronavirus disease 2019 (COVID-19) were first described in early December 2019 and has now spread to a global pandemic. While knowledge about COVID-19 continues to evolve, clinicians have reported hematologic complications associated with the virus.","Br J Haematol","Li, Monica","Nguyen, Charles B","Yeung, Zachary","Sanchez, Katherine","Rosen, Daniel","Bushan, Sita","32420629"],"abstract":["Evans syndrome (ES) is a rare condition characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia (ITP). While the precise pathophysiology is not entirely understood, it is believed that dysregulation of the immune system is a primary contributor to the condition. ES has been observed in viral infections including hepatitis C, cytomegalovirus, varicella-zoster, and Epstein-Barr viruses (1-4). Initial cases of coronavirus disease 2019 (COVID-19) were first described in early December 2019 and has now spread to a global pandemic. While knowledge about COVID-19 continues to evolve, clinicians have reported hematologic complications associated with the virus."],"journal":"Br J Haematol","authors":["Li, Monica","Nguyen, Charles B","Yeung, Zachary","Sanchez, Katherine","Rosen, Daniel","Bushan, Sita"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420629","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16846","locations":["Evans"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1667159284511670272,"score":239.28891},{"pmid":32453877,"title":"Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19).","text":["Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19).","COVID-19 can affect the hematopoietic system. Thrombocytopenia at admission was prevalent, while late-phase or delayed-phase thrombocytopenia (occurred 14 days after symptom onset) is obscure. This retrospective single-center study screened 450 COVID-19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25th to March 9th, 2020. COVID-19 associated delayed-phase thrombocytopenia occurred in 11.8% percent of enrolling patients. The delayed-phase thrombocytopenia in COVID-19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed-phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed-phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also presented bone marrow aspiration pathology of three patients with delayed-phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune mediated platelet destruction might account for the delayed-phase thrombocytopenia in a group of patients. Besides, clinicians need to pay attention to the delayed-phase thrombocytopenia especially at 3-4 weeks after symptom onset.","Br J Haematol","Chen, Wanxin","Li, Ziping","Yang, Bohan","Wang, Ping","Zhou, Qiong","Zhang, Zhiguo","Zhu, Jianhua","Chen, Xuexing","Yang, Peng","Zhou, Hao","32453877"],"abstract":["COVID-19 can affect the hematopoietic system. Thrombocytopenia at admission was prevalent, while late-phase or delayed-phase thrombocytopenia (occurred 14 days after symptom onset) is obscure. This retrospective single-center study screened 450 COVID-19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25th to March 9th, 2020. COVID-19 associated delayed-phase thrombocytopenia occurred in 11.8% percent of enrolling patients. The delayed-phase thrombocytopenia in COVID-19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed-phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed-phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also presented bone marrow aspiration pathology of three patients with delayed-phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune mediated platelet destruction might account for the delayed-phase thrombocytopenia in a group of patients. Besides, clinicians need to pay attention to the delayed-phase thrombocytopenia especially at 3-4 weeks after symptom onset."],"journal":"Br J Haematol","authors":["Chen, Wanxin","Li, Ziping","Yang, Bohan","Wang, Ping","Zhou, Qiong","Zhang, Zhiguo","Zhu, Jianhua","Chen, Xuexing","Yang, Peng","Zhou, Hao"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453877","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/bjh.16885","keywords":["covid-19","sars-cov-2","clinical features","cytokine","lymphocyte","thrombocytopenia"],"locations":["Thrombocytopenia","thrombocytopenia","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667881798485409792,"score":139.58911},{"pmid":32304491,"title":"COVID-19: guidance for infection prevention and control in nuclear medicine.","text":["COVID-19: guidance for infection prevention and control in nuclear medicine.","This guidance document is a brief consensus document covering the range and breadth of nuclear medicine practice in the UK, and identifies a few steps individual nuclear medicine practitioners and departments can take in the best interests of their patients. This guidance document should be used to inform local practice and does not replace local Trust policies or any relevant legislation. At all times, the best interests of the patients should be paramount. Please read this guidance in conjunction with previous editorial (COVID-19- Nuclear Medicine Departments, be prepared! by Huang HL, Allie R, Gnanasegaran G, Bomanji. J Nucl Med Commun 2020; 41:297-299). Although some aspects of this guidance are time-sensitive due to the nature of the global emergency, we believe that there is still sufficient information to provide some key guiding principles.","Nucl Med Commun","Buscombe, John R","Notghi, Alp","Croasdale, Jilly","Pandit, Manish","O'Brien, Joseph","Graham, Richard","Redman, Stewart","Vinjamuri, Sobhan","32304491"],"abstract":["This guidance document is a brief consensus document covering the range and breadth of nuclear medicine practice in the UK, and identifies a few steps individual nuclear medicine practitioners and departments can take in the best interests of their patients. This guidance document should be used to inform local practice and does not replace local Trust policies or any relevant legislation. At all times, the best interests of the patients should be paramount. Please read this guidance in conjunction with previous editorial (COVID-19- Nuclear Medicine Departments, be prepared! by Huang HL, Allie R, Gnanasegaran G, Bomanji. J Nucl Med Commun 2020; 41:297-299). Although some aspects of this guidance are time-sensitive due to the nature of the global emergency, we believe that there is still sufficient information to provide some key guiding principles."],"journal":"Nucl Med Commun","authors":["Buscombe, John R","Notghi, Alp","Croasdale, Jilly","Pandit, Manish","O'Brien, Joseph","Graham, Richard","Redman, Stewart","Vinjamuri, Sobhan"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304491","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MNM.0000000000001206","locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138491127332864,"score":128.33397},{"pmid":32296910,"title":"Mechanism of thrombocytopenia in COVID-19 patients.","text":["Mechanism of thrombocytopenia in COVID-19 patients.","Since December 2019, a novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. Some studies reported cases of thrombocytopenia, but hardly any studies mentioned how the virus causes thrombocytopenia. We propose several mechanisms by which coronavirus disease 2019 causes thrombocytopenia to better understand this disease and provide more clinical treatment options.","Ann Hematol","Xu, Panyang","Zhou, Qi","Xu, Jiancheng","32296910"],"abstract":["Since December 2019, a novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. Some studies reported cases of thrombocytopenia, but hardly any studies mentioned how the virus causes thrombocytopenia. We propose several mechanisms by which coronavirus disease 2019 causes thrombocytopenia to better understand this disease and provide more clinical treatment options."],"journal":"Ann Hematol","authors":["Xu, Panyang","Zhou, Qi","Xu, Jiancheng"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296910","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00277-020-04019-0","keywords":["coronavirus disease 2019","platelet","severe acute respiratory syndrome coronavirus 2","thrombocytopenia"],"locations":["China","thrombocytopenia","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493207707648,"score":127.542206}]}